← Back to Search

Chemotherapy

siG12D-LODER for Pancreatic Cancer (PROTACT Trial)

Phase 2

Waitlist Available

Led By Talia Golan, MD

Research Sponsored by Silenseed Ltd

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one year

Awards & highlights

PROTACT Trial Summary

This trial will test a new cancer drug in patients with unresectable or borderline resectable locally advanced pancreatic cancer. The primary outcome is ORR at 6 months.

Eligible Conditions

Pancreatic Cancer

PROTACT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

ORR at 6 months

PROTACT Trial Design

1Treatment groups

Experimental Treatment

Group I: siG12D-LODER + chemotherapyExperimental Treatment3 Interventions

Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Folfirinox

2018

Completed Phase 3

~760

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Silenseed LtdLead Sponsor

1 Previous Clinical Trials

15 Total Patients Enrolled

Talia Golan, MDPrincipal InvestigatorSheba Medical Center

1 Previous Clinical Trials

24 Total Patients Enrolled

Eileen M O'Reilly, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

1 Previous Clinical Trials

217 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment for this clinical experiment still taking place?

"This research initiative is no longer enrolling patients as the clinical trial was last updated on June 30th, 2021. However, if you are looking for other studies related to cancer of pancreas there are 1372 active trials and 1112 siG12D-LODER studies currently recruiting participants."

Answered by AI

Has the FDA approved siG12D-LODER for commercial use?

"Our in-house team at Power rated the security of siG12D-LODER a 2, alluding to its Phase 2 status, which demonstrates some evidence regarding safety but no efficacy data yet."

Answered by AI

What additional tests have been conducted on siG12D-LODER as a treatment?

"Presently, 1112 clinical trials are in operation investigating siG12D-LODER. Of these active studies, 321 are at the Phase 3 level. The vast majority of trials for this treatment take place in Shanghai, yet there over 59 thousand trial locations around the world."

Answered by AI

What medical conditions is siG12D-LODER typically prescribed for?

"siG12D-LODER is prescribed to patients suffering from advanced neoplasm metastasis, as well as locally advanced non-small cell lung cancer, metastatic bladder cancer and urinary bladder maladies."

Answered by AI

How many participants have joined this trial thus far?

"Unfortunately, this clinical trial has ceased recruitment activities. It was initially posted on March 7th 2018 and last edited on June 30th 2021. On the other hand, there are currently 1372 trials enrolling patients with pancreatic cancer and 1112 recruiting for siG12D-LODER related studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

2018. "A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01676259.